Highlighting the recent evidence on Hsp90 pharmacology, this review discusses that Hsp90 inhibition could signify a potential strategy in GBM therapy by targeting various factors in recurrence, invasion, treatment resistance, and, most importantly, neurodegeneration. This evidence concerns the gene HSP90AA1 and glioblastoma.